Hypofractionated Radiotherapy Plus ICI for Bladder Cancer Limited by Toxicity - Targeted Oncology

Sophia Kamran, MD, discusses potential toxicities limiting the addition of immunotherapy to trimodal therapy for patients with urothelial cancer.

Sophia Kamran, MD, a radiation oncologist at Massachusetts General Hospital and assistant professor of radiation oncology at Harvard Medical School, discusses potential toxicities limiting the additi… [+2852 chars]

full article...